TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06067841: A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Sponsor: Bristol-Myers Squibb · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 140 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$7,131,432

Rescue Site Savings

+$4,712,400

Unlock Full NCT06067841 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06067841 Rescue Dossier →